Effect of Acupuncture on Opioid-associated Constipation in Cancer Patients

Trial Title: Effect of Acupuncture on Opioid-associated Constipation in Cancer Patients

NCT ID: NCT06537440

Condition: Opioid-associated Constipation in Cancer Patients

Conditions: Official terms:
Constipation

Conditions: Keywords:
Acupuncture
Opioid-related constipation

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: Double (Participant, Investigator)

Masking description: Due to the specific nature of acupuncture clinical research, it is difficult to accomplish double blinding of subjects and operators, so this trial was blinded to subjects and statisticians only. The statistical analyst was a non-subject and was not aware of the patient treatment or the trial protocol. For all patients who participated in acupuncture, blinded evaluation questions were asked at the 2nd week after acupuncture.

Intervention:

Intervention type: Other
Intervention name: electro-acupuncture
Description: Electroacupuncture ST25 Tianshu (double), TE6 Zhigou (double), LI4 Hegu (double), ST36 Ashisanli (double), ST37 Shangjuhu (double)
Arm group label: Acupuncture group
Arm group label: Sham Acupuncture group

Summary: To evaluate the efficacy and safety of acupuncture for opioid-associated constipation in cancer patients.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Cancer patients must meet the diagnostic criteria of Rome IV Opioid-Related Constipation: (1) Constipation or worsening of constipation symptoms with opioid use or dose change, etc., must include 2 or more of the following: (1) at least 25% of bowel movements are labored; (2) at least 25% of bowel movements are dry ball or hard stools; (3) at least 25% of bowel movements are incomplete; (4) at least 25% of bowel movements have anal rectal obstruction and/or blockage in at least 25% of the bowel movements; (5) at least 25% of the bowel movements required manual assistance (e.g., finger-assisted defecation, pelvic floor support); less than 3 bowel movements per week; (2) the rare occurrence of loose stools when laxatives were not used. 2. Patients recruited for this trial must have at least a 1-week history of opioid-associated constipation symptoms. 3. Patients must be between 18 and 85 years of age. 4. Patients with stable cancer status and an expected survival of >3 months 5. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. 6. Prior to cancer pain screening, patients must be on a relatively stable opioid regimen consisting of 30 mg to 1000 mg oral morphine equivalents daily for at least 2 weeks. In addition, opioids are expected to be maintained for at least 10 weeks. 7. The patient's spontaneous bowel movement (SBM) frequency is 2 times per week without laxatives. 8. Patients must have the ability to take oral medications, food, and drink. 9. A voluntary signed patient informed consent form Exclusion Criteria: 1. Patients diagnosed with clinically significant defecation abnormalities due to abnormalities of the gastrointestinal tract and other tissues associated with the gastrointestinal tract (excluding OIC): inflammatory bowel disease, rectal prolapse, gastrointestinal obstruction, peritoneal metastases, or peritoneal tumors 2. Patients with a history of gastrointestinal surgery, abdominal surgery, or abdominal adhesions within one month prior to screening; patients with a history of intestinal obstruction within three months prior to screening 3. Diagnosis of active diverticular disease, severe hemorrhoids, anal fissures; or artificial rectum or anus 4. Patients with an intra-abdominal catheter or feeding tube 5. Diagnosis of pelvic disease that significantly affects intestinal transport of feces (e.g., uterine prolapse ≥ 2 degrees, uterine fibroids [located in the posterior part of the uterus, ≥ 5 cm in diameter] affecting intestinal motility) 6. Patients who are receiving new chemotherapy for cancer within 14 days prior to screening, who have never had chemotherapy in the past, or who are scheduled to receive chemotherapy during the study period 7. Patients who have received radiotherapy within 28 days prior to screening or are scheduled to receive radiotherapy during the study period 8. Patients who have undergone a procedure or intervention that has a significant impact on gastrointestinal function within 28 days prior to screening or who are scheduled to undergo a procedure or intervention that has a significant impact on gastrointestinal function during the study period or who are scheduled to undergo a procedure or intervention that may prevent the patient from completing the trial 9. Patients with uncontrolled hyperthyroidism, severe hypertension, heart disease, systemic infection, or blood clotting disorders (hypercoagulable state or bleeding tendencies) at the time of study inclusion 10. Patients who consumed >4 additional opioid doses per day for more than 3 days during the baseline period due to fulminant pain or who changed their maintenance opioid dosing regimen during this period 11. Patients with severe cancer pain (e.g., typical average daily pain intensity rating of 7 to 10 (NRS; 0 [no pain] to 10 [worst possible pain]) following treatment with conventional doses and frequency of opioids 12. Patients with a history of opioid discontinuation due to a serious adverse event or patients with anticipated opioid discontinuation due to a potential risk of adverse events 13. Patients who have received an opioid receptor antagonist within one month of screening or who are scheduled to receive such treatment during the study period 14. Patients with a history of neuroleptic release 15. Patients with severe cognitive impairment, aphasia or psychiatric disorder; abdominal aortic aneurysm; hepatomegaly (liver span >14 cm at midclavicular line on ultrasound); or splenomegaly (spleen length [from head to tail] >13 cm on ultrasound) 16. Patients who had received acupuncture treatment within the previous three months were screened. 17. Other patients who were deemed ineligible for the study by the investigator based on combined treatment and medical outcomes

Gender: All

Minimum age: 18 Years

Maximum age: 85 Years

Healthy volunteers: No

Locations:

Facility:
Name: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Address:
City: Tianjin
Zip: 300193
Country: China

Status: Recruiting

Contact:
Last name: Fanming Kong

Phone: +86 022-27986525
Email: kongfanming08@163.com

Start date: August 1, 2024

Completion date: May 22, 2025

Lead sponsor:
Agency: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Agency class: Other

Source: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06537440